Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Endocrinol Metab ; 86(7): 3359-67, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11443212

ABSTRACT

The endometrium is a tissue unique for its cyclic destruction and rapid regeneration of blood vessels. Angiogenesis, indispensable for the regeneration process, provides a richly vascularized, receptive endometrium fundamental for implantation, placentation, and embryogenesis. Human endometrial microvascular endothelial cells (hEMVEC) were isolated to better understand the properties and angiogenic behavior of these cells. Unlike human foreskin microvascular endothelial cells (hFMVEC), which proliferated better upon stimulation by basic fibroblast growth factor, hEMVEC were much more sensitive to vascular endothelial growth factor A (VEGF-A) stimulation, probably due to enhanced VEGF receptor 2 expression. In addition, hEMVEC displayed an enhanced expression of the urokinase-type plasminogen activator (u-PA) compared with hFMVEC. No differences were found in tissue-type PA, PA inhibitor-1, and u-PA receptor expression. The high expression of u-PA by hEMVEC was also found in tissue sections. hEMVEC formed capillary-like structures when cultured in 20% human serum on top of three-dimensional fibrin matrices, and VEGF-A or basic fibroblast growth factor increased this tube formation. This is in contrast with hFMVEC, which formed tubes only after simultaneous stimulation by a growth factor and tumor necrosis factor-alpha. The high basal level of u-PA contributes to and may explain the higher angiogenic properties of hEMVEC (in vitro).


Subject(s)
Endometrium/blood supply , Endothelium, Vascular/physiology , Neovascularization, Physiologic , Urokinase-Type Plasminogen Activator/analysis , Capillaries/physiology , Cell Division , Cell Separation , Cells, Cultured , Endometrium/enzymology , Endothelial Growth Factors/pharmacology , Endothelium, Vascular/cytology , Endothelium, Vascular/enzymology , Female , Fibroblast Growth Factor 2/pharmacology , Humans , Menstrual Cycle , Plasminogen Activator Inhibitor 1/biosynthesis , Plasminogen Activators/biosynthesis , Receptors, Cell Surface/analysis , Receptors, Cell Surface/metabolism , Receptors, Urokinase Plasminogen Activator , Tissue Plasminogen Activator/biosynthesis , Tumor Necrosis Factor-alpha/pharmacology , Urokinase-Type Plasminogen Activator/biosynthesis , Vascular Endothelial Growth Factor A
2.
Thromb Haemost ; 85(2): 296-302, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11246551

ABSTRACT

Among other proteolytic enzymes, the urokinase-type plasminogen activator (u-PA)/plasmin cascade contributes to cell migration and the formation of capillary-like structures in a fibrinous exudate. The u-PA receptor (u-PAR) focuses proteolytical activity on the cell surface of the endothelial cell and hereby accelerates the pericellular matrix degradation. Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF)-2 enhance u-PA receptor expression in human endothelial cells. In this paper we show that the protein kinase C (PKC) inhibitors Ro31-8220 and GF109203X inhibit VEGF165-induced u-PAR antigen expression in human endothelial cells, whereas PKC inhibition had no effect on FGF-2-induced u-PAR antigen enhancement. In addition, inhibition of PKC activity had no effect on VEGF165- or FGF-2-induced proliferation in human endothelial cells. We conclude that VEGF165 induces u-PAR via a PKC-dependent pathway, whereas proliferation is induced via a different pathway probably involving tyrosine phosphorylation of proteins downstream of the VEGF receptors.


Subject(s)
Endothelial Growth Factors/pharmacology , Endothelium, Vascular/drug effects , Lymphokines/pharmacology , Protein Kinase C/physiology , Receptors, Cell Surface/drug effects , Cell Division/drug effects , Cells, Cultured , Endothelial Growth Factors/physiology , Endothelium, Vascular/cytology , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Fibroblast Growth Factors/pharmacology , Humans , Indoles/pharmacology , Lymphokines/physiology , Maleimides/pharmacology , Plasminogen Activators/antagonists & inhibitors , Plasminogen Activators/drug effects , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/metabolism , Receptors, Cell Surface/antagonists & inhibitors , Receptors, Urokinase Plasminogen Activator , Signal Transduction , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
3.
J Cell Sci ; 114(Pt 4): 825-33, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11171387

ABSTRACT

Hypoxia in combination with a growth factor is a strong inducer of angiogenesis. Among several effects, hypoxia can activate endothelial cells directly, but the mechanism by which it acts is not fully elucidated. In vitro, human microvascular endothelial cells (hMVEC) form capillary-like tubules in fibrin solely after stimulation with a combination of fibroblast growth factor (FGF)-2 or vascular endothelial growth factor (VEGF) and the cytokine tumour necrosis factor (TNF)alpha. We show in this paper that in hypoxic conditions, FGF-2-stimulated hMVEC form tube-like structures in a fibrin matrix in the absence of TNFalpha. Hypoxia/FGF-2-stimulated cells express more urokinase-type plasminogen activator (u-PA) receptor than normoxia/FGF-2-stimulated cells and display a slightly higher turnover of u-PA. This small increase in u-PA activation probably cannot fully explain the hypoxia/FGF-2-induced tube formation. Hypoxia activated at least two signal pathways that may contribute to the enhanced angiogenic response. In hypoxia/FGF-2-stimulated hMVEC the transcription factor p65 was activated and translocated to the nucleus, whereas in normoxia/FGF-2-stimulated cells p65 remained inactive. Furthermore, in hypoxic conditions, the amounts of phosphorylated mitogen-activated protein kinases ERK1/2 were increased compared to normoxic conditions. We conclude that hypoxia is able to activate different signal pathways in FGF-2-stimulated human endothelial cells, which may be involved in hypoxia-induced angiogenesis.


Subject(s)
Cell Hypoxia , Endothelium, Vascular/drug effects , Fibrin/metabolism , Fibroblast Growth Factor 2/pharmacology , Neovascularization, Physiologic , Signal Transduction , Cell Line , Endothelium, Vascular/cytology , Endothelium, Vascular/metabolism , Humans , NF-kappa B/metabolism , Phosphorylation , Protein Kinases/metabolism , Receptors, Cell Surface/biosynthesis , Receptors, Urokinase Plasminogen Activator
4.
Angiogenesis ; 4(1): 53-60, 2001.
Article in English | MEDLINE | ID: mdl-11824379

ABSTRACT

Different forms of vascular endothelial growth factor (VEGF) and their cellular receptors (VEGFR) are associated with angiogenesis, as demonstrated by the lethality of VEGF-A, VEGFR-1 or VEGFR-2 knockout mice. Here we have used an in vitro angiogenesis model, consisting of human microvascular endothelial cells (hMVEC) cultured on three-dimensional (3D) fibrin matrices to investigate the roles of VEGFR-1 and VEGFR-2 in the process of VEGF-A and VEGF-C-induced tube formation. Soluble VEGFR-1 completely inhibited the tube formation induced by the combination of VEGF-A and TNF alpha (VEGF-A/TNF alpha). This inhibition was not observed when tube formation was induced by VEGF-C/TNF alpha or bFGF/TNF alpha. Blocking monoclonal antibodies specific for VEGFR-2, but not antibodies specifically blocking VEGFR-1, were able to inhibit the VEGF-A/TNF alpha-induced as well as the VEGF-C/TNF alpha-induced tube formation in vitro. P1GF-2, which interacts only with VEGFR-1, neither induced tube formation in combination with TNF alpha, nor inhibited or stimulated by itself the VEGF-A/TNF alpha-induced tube formation in vitro. These data indicate that VEGF-A or VEGF-C activation of the VEGFR-2, and not of VEGFR-1, is involved in the formation of capillary-like tubular structures of hMVEC in 3D fibrin matrices used as a model of repair-associated or pathological angiogenesis in vitro.


Subject(s)
Endothelial Growth Factors/pharmacology , Endothelium, Vascular/drug effects , Endothelium, Vascular/growth & development , Neovascularization, Physiologic/drug effects , Proto-Oncogene Proteins/physiology , Receptor Protein-Tyrosine Kinases/physiology , Receptors, Growth Factor/physiology , Animals , Antibodies, Monoclonal/pharmacology , Cells, Cultured , Endothelium, Vascular/physiology , Humans , In Vitro Techniques , Mice , Models, Cardiovascular , Proto-Oncogene Proteins/antagonists & inhibitors , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Receptors, Growth Factor/antagonists & inhibitors , Receptors, Vascular Endothelial Growth Factor , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factor C , Vascular Endothelial Growth Factor Receptor-1
5.
Blood ; 96(8): 2775-83, 2000 Oct 15.
Article in English | MEDLINE | ID: mdl-11023511

ABSTRACT

Hypoxia stimulates angiogenesis, the formation of new blood vessels. This study evaluates the direct effect of hypoxia (1% oxygen) on the angiogenic response of human microvascular endothelial cells (hMVECs) seeded on top of a 3-dimensional fibrin matrix. hMVECs stimulated with fibroblast growth factor-2 (FGF-2) or vascular endothelial growth factor (VEGF) together with tumor necrosis factor-alpha (TNF-alpha) formed 2- to 3-fold more tubular structures under hypoxic conditions than in normoxic (20% oxygen) conditions. In both conditions the in-growth of capillary-like tubular structures into fibrin required cell-bound urokinase-type plasminogen activator (uPA) and plasmin activities. The hypoxia-induced increase in tube formation was accompanied by a decrease in uPA accumulation in the conditioned medium. This decrease in uPA level was completely abolished by uPA receptor-blocking antibodies. During hypoxic culturing uPA receptor activity and messenger RNA (mRNA) were indeed increased. This increase and, as a consequence, an increase in plasmin formation contribute to the hypoxia-induced stimulation of tube formation. A possible contribution of VEGF-A to the increased formation under hypoxic conditions is unlikely because there was no increased VEGF-A expression detected under hypoxic conditions, and the hypoxia-induced tube formation by FGF-2 and TNF-alpha was not inhibited by soluble VEGFR-1 (sVEGFR-1), or by antibodies blocking VEGFR-2. Furthermore, although the alpha(v)-integrin subunit was enhanced by hypoxia, blocking antibodies against alpha(v)beta(3)- and alpha(v)beta(5)-integrins had no effect on hypoxia-induced tube formation. Hypoxia increases uPA association and the angiogenic response of human endothelial cells in a fibrin matrix; the increase in the uPA receptor is an important determinant in this process. (Blood. 2000;96:2775-2783)


Subject(s)
Endothelium, Vascular/metabolism , Hypoxia/physiopathology , Neovascularization, Pathologic/physiopathology , Receptors, Cell Surface/biosynthesis , Antigens, CD/biosynthesis , Antigens, CD/genetics , Cell Hypoxia , Cell Survival , Cells, Cultured , Culture Media , Culture Media, Conditioned , DNA, Complementary/genetics , Endothelial Growth Factors/pharmacology , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Extracellular Matrix , Fibrin , Fibrinolysin/physiology , Fibroblast Growth Factor 2/pharmacology , Gene Expression Regulation/drug effects , Humans , Integrin alphaV , Integrins/antagonists & inhibitors , Integrins/immunology , Lymphokines/pharmacology , Morphogenesis/physiology , Oxygen/pharmacology , Proto-Oncogene Proteins/physiology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Receptor Protein-Tyrosine Kinases/immunology , Receptor Protein-Tyrosine Kinases/physiology , Receptors, Cell Surface/genetics , Receptors, Growth Factor/antagonists & inhibitors , Receptors, Growth Factor/immunology , Receptors, Urokinase Plasminogen Activator , Receptors, Vascular Endothelial Growth Factor , Receptors, Vitronectin/antagonists & inhibitors , Receptors, Vitronectin/immunology , Tumor Necrosis Factor-alpha/pharmacology , Urokinase-Type Plasminogen Activator/physiology , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factor Receptor-1 , Vascular Endothelial Growth Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...